Completed OBSERVATIONAL NCT00897533

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503

Sponsor: ECOG-ACRIN Cancer Research Group

Interventions diagnostic laboratory biomarker analysis gene mapping immunohistochemistry staining method polymorphism analysis

Updated 7 times since 2017 Last updated: May 17, 2017 Started: Apr 13, 2007 Primary completion: Apr 13, 2008 Completion: Apr 13, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00897533, this observational or N/A phase trial focuses on Lung Cancer and remains completed. Sponsored by ECOG-ACRIN Cancer Research Group, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Jun 2017 — Apr 2018 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2017 — Jun 2017 [monthly]

Unknown Status NA

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.